IMNN(IMNN)
IMNN
ANALYST COVERAGE4 analysts
BUY
▲ +344.4%upside to target
Key MetricsTTM
Market Cap$5.62M
Revenue TTM$0.00
Net Income TTM-$14.64M
Free Cash Flow-$15.06M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-341.2%
Return on Assets-182.6%
Debt / Equity0.27
Current Ratio1.59
EPS TTM$-2.91
PRICE
Prev Close
2.15
Open
2.14
Day Range2.14 – 2.25
2.14
2.25
52W Range2.08 – 41.22
2.08
41.22
0% of range
VOLUME & SIZE
Avg Volume
89.6K
FUNDAMENTALS
P/E Ratio
-0.5x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.17
Market-like
TECHNICAL
RSI (14)
24
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30
IMNN News
About
celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Michael Tardugno
Website
Douglas V. FallerChief Medical Officer
Stacy R. LindborgPresident, Chief Executive Officer & Director
Jeffrey W. ChurchInterim Chief Financial Officer
Michael H. TardugnoExecutive Chairman
Timothy J. TumminelloChief Accounting Officer & Controller
Kristin LongobardiSenior Vice President of Strategic Operations
Susan Mary EylwardGeneral Counsel & Corporate Secretary